Igor Puzanov
Igor Puzanov
Verified email at
Cited by
Cited by
Inhibition of mutated, activated BRAF in metastatic melanoma
KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ...
New England Journal of Medicine 363 (9), 809-819, 2010
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ...
New England Journal of Medicine 367 (18), 1694-1703, 2012
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline
JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ...
Journal of Clinical Oncology 36 (17), 1714-1768, 2018
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ...
Journal of clinical oncology 32 (10), 1020, 2014
Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib
JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ...
New England Journal of Medicine 366 (8), 707-714, 2012
Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
RHI Andtbacka, HL Kaufman, F Collichio, T Amatruda, N Senzer, ...
Journal of clinical oncology 33 (25), 2780-2788, 2015
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ...
Nature 467 (7315), 596-599, 2010
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ...
New England Journal of Medicine 373 (8), 726-736, 2015
Fulminant myocarditis with combination immune checkpoint blockade
DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ...
New England Journal of Medicine 375 (18), 1749-1755, 2016
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ...
The lancet oncology 16 (8), 908-918, 2015
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I Puzanov, A Diab, K Abdallah, CO Bingham, C Brogdon, R Dadu, ...
Journal for immunotherapy of cancer 5 (1), 1-28, 2017
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ...
New England Journal of Medicine 366 (3), 207-215, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
K Margolin, MS Ernstoff, O Hamid, D Lawrence, D McDermott, I Puzanov, ...
The lancet oncology 13 (5), 459-465, 2012
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ...
Cell 170 (6), 1109-1119. e10, 2017
Combined nivolumab and ipilimumab in melanoma metastatic to the brain
HA Tawbi, PA Forsyth, A Algazi, O Hamid, FS Hodi, SJ Moschos, ...
New England Journal of Medicine 379 (8), 722-730, 2018
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
GV Long, U Trefzer, MA Davies, RF Kefford, PA Ascierto, PB Chapman, ...
The lancet oncology 13 (11), 1087-1095, 2012
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
NB Haas, J Manola, RG Uzzo, KT Flaherty, CG Wood, C Kane, M Jewett, ...
The Lancet 387 (10032), 2008-2016, 2016
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ...
JAMA oncology 2 (2), 234-240, 2016
Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with …
J Chesney, I Puzanov, F Collichio, P Singh, MM Milhem, J Glaspy, ...
Journal of clinical oncology 36 (17), 1658, 2018
Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma
I Puzanov, MM Milhem, D Minor, O Hamid, A Li, L Chen, M Chastain, ...
Journal of Clinical Oncology 34 (22), 2619, 2016
The system can't perform the operation now. Try again later.
Articles 1–20